Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...

Telehealth and wellness platform Hims & Hers on Monday offered a revenue outlook for the year ahead that topped Wall Street’s expectations, but shares fell hard in after-hours trading ...

Hims and Hers' stock fell over 19% in after-hours trading on Monday after its CEO said the company would no longer sell compounded versions of mega-hit weight loss drugs. "We will have to start ...

Shares of Hims & Hers Health closed down 22% on Tuesday, a day after the telehealth company released fourth-quarter results that disappointed on gross margin and sparked concerns about the future ...

Hims & Hers reported a double beat with Q4 revenue at $481M, a 95% YoY improvement, but faced an 18% stock drop after hours. Despite margin contraction due to new weight loss offerings, adjusted ...

Hims & Hers (HIMS) stock plunged 27% on Tuesday after the telehealth highflier indicated it may soon stop offering some compounded versions of weight-loss drugs. The company's fourth quarter ...

Hims & Hers Health shares plunged 18% in extended trading on Monday after investors looked past better-than-expected revenue and earnings and focused instead on the disappointing gross margin ...

Direct-to-consumer telehealth company Hims & Hers is forging ahead in the aftermath of the semaglutide shortage ending last week. Hims & Hers faces new headwinds in its weight management segment ...

Hims & Hers Health, Inc. (HIMS) reported its fourth-quarter 2024 earnings, revealing an EPS of $0.11, falling short of the forecasted $0.17. Revenue for the quarter reached $481 million ...

Online health and wellness company Hims & Hers reported fourth-quarter earnings that beat Wall Street analysts' expectations and gave upbeat guidance for 2025. But shares of the company dropped 19 ...

Hims & Hers Health (NYSE:HIMS) is set to report its earnings on Monday, Feb 24 after market close. HIMS stock plunged over 25% on Friday, Feb 21, after the U.S. FDA announced semaglutide is no ...